Catalyst Wire Dossier Catalyst Wire Dossier

Latanoprost Ophthalmic Solution 0.005%

latanoprost
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Latanoprost Ophthalmic Solution 0.005%, covering 2022-05-25 to 2022-05-25. Get the full timeline:

Most recent: Clinical Trial Update: Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure [Phase 3]

See pricing